vesicular
stomat
viru
vsv
extens
util
viral
vector
system
induct
protect
immun
respons
varieti
pathogen
construct
recombin
vsv
specifi
either
indiana
chandipura
viru
g
glycoprotein
express
west
nile
viru
wnv
envelop
e
glycoprotein
mice
intranas
vaccin
use
prime
indiana
boost
chandipura
immun
approach
challeng
virul
ninetyperc
vaccin
mice
surviv
compar
mockvaccin
mice
wnv
lethal
challeng
histopatholog
examin
brain
tissu
reveal
neuron
necrosi
mockvaccin
mice
vaccin
mice
vaccin
mockvaccin
mice
develop
strong
neutral
antibodi
respons
wnv
extens
immunolog
analysi
use
polychromat
flow
cytometri
stain
reveal
vaccin
mockvaccin
mice
develop
robust
cellular
immun
respons
evidenc
upregul
cell
vaccin
mockvaccin
mice
similarli
vaccin
mice
develop
robust
eglycoproteinspecif
cell
immun
respons
evidenc
presenc
high
percentag
low
cell
addit
sizeabl
popul
cell
detect
indic
especif
activ
matur
cell
low
regulatori
reg
cell
downregul
result
suggest
vsvvector
vaccin
administ
intranas
effici
induc
protect
humor
cellular
immun
respons
wnv
infect
west
nile
viru
wnv
first
isol
year
ago
febril
patient
west
nile
provinc
uganda
wnv
positivesens
rna
viru
belong
genu
flaviviru
falvivirida
famili
lipidbilay
membran
nascent
viru
contain
molecul
envelop
e
premembran
prem
protein
organ
asymmetr
nonneurolog
clinic
manifest
includ
rhabdomyolysi
pancreat
hepat
myositi
orchiti
chorioretin
cardiac
dysrhythmia
typic
less
patient
suffer
west
nile
neuroinvas
diseas
wnd
includ
west
nile
mening
wnm
enceph
wne
acut
flaccid
paralysi
poliomyelitislik
syndrom
wnp
among
wnd
case
estim
patient
wne
result
estim
case
fatal
addit
mortal
human
could
attribut
wnp
absenc
effect
treatment
wnv
infect
encourag
vaccin
develop
varieti
differ
approach
employ
produc
wnv
vaccin
includ
inactiv
viru
subunit
dnabas
vaccin
vaccin
appear
highli
immunogen
case
protect
wnvinfect
experiment
anim
recent
recombin
virus
express
wnv
antigen
shown
induc
strong
immun
respons
protect
wnv
challeng
anim
specif
recombin
live
canarypoxvector
vaccin
express
prem
protein
e
glycoprotein
induc
strong
immun
respons
hors
cat
appear
partial
protect
viralvector
vaccin
elicit
protect
immun
respons
mice
includ
lentiviru
vector
base
vaccin
trips
wnv
measl
virusvector
vaccin
recombin
yellow
fever
viru
yfv
also
use
express
wnv
prem
e
protein
base
extens
safeti
record
yfv
attenu
vaccin
yfv
recombin
vaccin
chimerivax
tm
shown
good
immun
respons
hamster
mice
nonhuman
primat
human
phase
ii
clinic
trial
chimerivax
tm
wnv
current
underway
vsv
envelop
neg
strand
rna
viru
belong
rhabdovirida
famili
natur
vsv
infect
human
rare
caus
mild
flulik
ill
vsv
infecti
virus
effici
recov
revers
genet
approach
util
multipl
plasmid
express
vsv
gene
methodolog
enabl
rapid
construct
recombin
vsv
virus
express
varieti
viral
bacteri
antigen
vaccin
purpos
includ
influenza
viru
bovin
diarrhea
viru
cottontail
papillomaviru
human
immunodefici
viru
simian
immunodefici
viru
respiratori
syncyti
viru
hepat
c
measl
viru
ebola
viru
lassa
fever
viru
marburg
viru
sever
acut
respiratori
syndrom
viru
sar
herp
simplex
viru
recombin
vsv
also
construct
test
vaccin
bacteri
pathogen
includ
mycobacterium
tuberculosi
yersinia
pesti
vsvvector
vaccin
administ
via
intranas
intramuscular
subcutan
rout
shown
elicit
robust
mucos
system
humor
cellular
immun
respons
construct
recombin
vsv
express
wnv
e
glycoprotein
primeboost
approach
employ
util
two
differ
recombin
vsv
express
either
indiana
chandipura
g
glycoprotein
prime
boost
immun
respect
intranas
immun
mice
confer
high
protect
lethal
challeng
virul
wnv
strain
neuron
necrosi
observ
mockvaccin
vaccin
mice
result
suggest
vsv
recombin
vaccin
express
wnv
e
glycoprotein
may
efficaci
intranas
vaccin
anim
human
use
babi
hamster
kidney
cell
obtain
american
tissu
cultur
collect
atcc
cell
grown
use
dulbecco
modifi
minim
essenti
media
dmem
supplement
fetal
bovin
serum
fb
appropri
amount
antibiot
west
nile
viru
envelop
e
gene
obtain
first
produc
cdna
e
gene
strain
subsequ
clone
gene
plasmid
invitrogen
inc
pcr
amplif
e
gene
amplifi
pcr
plasmid
use
primer
introduc
uniqu
noti
bamhi
site
use
wneflagnoti
gacgacgcggccgcatgtttaactgccttggaa
wneflagbamhi
gcagcaggatccagcgtgcacgttcacgg
primer
noti
bamhi
site
italic
fragment
clone
plasmid
sigma
place
flag
epitop
code
sequenc
downstream
infram
e
glycoprotein
sequenc
recombin
plasmid
confirm
restrict
endonucleas
digest
dna
sequenc
cell
transfect
wnv
plasmid
use
lipofectamin
invitrogen
suggest
manufactur
e
glycoprotein
detect
h
posttransfect
use
antiflag
sigma
antiwest
nile
rabbit
polyclon
antibodi
abcam
immunofluoresc
assay
ifa
cell
wash
twice
phosphat
buffer
salin
pb
fix
icecold
methanol
cell
wash
pb
well
block
bsa
goat
serum
tb
trisbuff
salin
h
mous
antiflag
antibodi
sigma
block
buffer
rabbit
antiwnv
antibodi
ad
respect
well
dilut
incub
h
room
temperatur
cell
wash
six
time
tb
secondari
antibodi
alexa
fluor
goat
antimous
igg
goat
antirabbit
igg
invitrogen
ad
respect
well
dilut
cell
incub
dark
h
final
cell
wash
six
time
tb
observ
fluoresc
microscop
plasmid
clone
effici
express
wnv
e
gene
use
templat
pcr
amplif
gene
time
introduc
uniqu
xhoi
nhei
site
end
gene
fragment
use
ccgcggctcgagatgttt
gacgacgctagcggatcactac
primer
xhoi
nhei
restrict
site
italic
dna
fragment
clone
transfer
vector
cell
infect
recombin
vaccinia
viru
express
polymeras
multipl
infect
moi
h
subsequ
bhk
cell
cotransfect
pbsn
pbsp
pbsl
contain
wnv
e
gene
recombin
viru
recov
describ
detail
previous
control
virus
exogen
insert
gene
also
produc
use
pbsn
pbsp
pbsl
empti
vector
antiflag
antiwnv
antibodi
use
detect
express
e
glycoprotein
ifa
vsvinfect
bhk
cell
viral
isol
express
high
amount
wnv
e
glycoprotein
select
multipl
round
plaqu
purif
viral
titer
determin
stock
store
c
vaccin
studi
anim
studi
carri
appropri
approv
obtain
lsu
institut
anim
care
use
committe
iacuc
biosafeti
committe
four
group
ten
femal
balbc
mice
harlan
usa
use
studi
individu
mous
identifi
ear
tag
nation
band
tag
compani
ky
usa
group
vaccin
group
anim
mildli
anesthet
inhal
isofluran
l
dose
vaccin
contain
pfu
vaccin
rvsvinwnv
e
administ
intranas
use
l
pipett
l
per
nostril
anim
boost
rvsvchwnv
e
day
postvaccin
use
techniqu
one
mous
group
includ
fluorescenceactiv
cell
sort
fac
analysi
due
sampl
prepar
problem
n
group
ii
control
vaccin
group
control
group
anim
vaccin
way
describ
except
inocul
l
uninfect
cell
cultur
supernat
anim
boost
day
postvaccin
uninfect
cell
cultur
supernat
anim
belong
group
ii
human
euthan
day
postboost
spleen
collect
eppendorf
tube
contain
rpmi
process
flow
cytometri
intracellular
cytokin
cellsurfac
marker
associ
memori
cell
regulatori
cell
cytotox
cell
among
other
serolog
anim
bled
submandibular
rout
cheek
bleed
use
goldenrod
lancet
medipoint
ny
anim
bled
day
postvaccin
day
postboost
blood
collect
becton
dickinson
microtain
serum
separ
becton
dickinson
anim
treat
exactli
way
group
ii
boost
stage
day
postboost
anim
transport
anim
biosafeti
facil
acclimat
blood
collect
day
postboost
challeng
anim
challeng
intraperitoni
pfu
observ
time
day
day
anim
show
sever
neurolog
symptom
like
ataxia
hunch
postur
human
euthan
dead
anim
surgic
process
immedi
thorac
abdomin
caviti
open
place
formalin
jar
patholog
studi
serum
sampl
inactiv
incub
c
min
serial
twofold
dilut
serum
incub
equal
volum
pfu
c
h
serumviru
mixtur
ad
vero
cell
monolay
plate
triplic
plate
incub
anoth
hour
plate
overlaid
dulbecco
modifi
minimum
essenti
media
dmem
contain
methyl
cellulos
fetal
bovin
serum
plate
incub
c
h
fix
formalin
phosphat
buffer
salin
pb
plate
wash
three
time
pb
stain
crystal
violet
plaqu
count
highest
dilut
serum
result
reduct
plaqu
note
mous
splenocyt
adjust
cellsml
onehundr
microlitr
aliquot
splenocyt
suspens
incub
appropri
dilut
concentr
antibodi
min
room
temperatur
cell
wash
pb
fix
bd
stabil
fix
buffer
bd
bioscienc
distil
water
cell
kept
protect
light
c
flow
cytometr
acquisit
complet
within
h
stain
polychromat
paramet
flow
cytometr
acquisit
perform
lsr
ii
becton
dickinson
instrument
three
laser
nm
blue
laser
nm
red
laser
violet
laser
use
fitc
petexa
red
apc
pacif
blue
avail
fluorochrom
paramet
singlestain
control
fluorochrom
use
set
flow
cytometri
compens
monoclon
antibodi
includ
fitc
ebiosci
petexa
red
invitrogen
apc
bd
bioscienc
bd
bioscienc
pacif
blue
bd
bioscienc
use
least
event
collect
gate
cell
data
analyz
use
flowjo
softwar
treestar
inc
version
test
lymphocyt
subset
product
intracellular
cytokin
flow
cytometri
cfc
assay
employ
respons
wnv
peptid
pool
stimul
describ
previous
briefli
process
splenocyt
resuspend
cellsml
complet
fc
stimul
differ
wnv
peptid
pool
final
concentr
gml
peptid
pool
peptid
pool
amino
acid
overlap
deriv
wnv
e
glycoprotein
base
e
amino
acid
sequenc
nih
biodefens
emerg
infect
research
resourc
repositori
niaid
nih
peptid
array
divid
gener
two
peptid
pool
peptid
pool
made
peptid
peptid
pool
compos
peptid
posit
control
pma
ngml
sigma
ionomycin
gml
sigma
use
neg
control
antigen
mitogen
stimul
brefeldin
gml
sigma
ad
cultur
first
hour
incub
period
follow
stimul
cell
stain
cellsurfac
marker
directli
conjug
mab
fitc
bd
bioscienc
petr
pacif
blue
min
room
temperatur
wash
dpbsbsa
wash
buffer
cell
fix
permeabil
use
cytofixcytoperm
bd
bioscienc
wash
twice
perm
buffer
bd
bioscienc
stain
intracellular
mab
pe
bd
bioscienc
andor
apc
ebiosci
ad
cell
incub
room
temperatur
min
singl
color
isotypematch
control
antibodi
use
confirm
stain
specif
wash
cell
resuspend
paraformaldehyd
pb
store
dark
c
data
acquir
within
h
stain
use
lsr
ii
instrument
bd
immunocytometri
system
facsdiva
softwar
bd
immunocytometri
system
sampl
event
collect
gate
cell
data
analysi
perform
use
flowjo
softwar
gate
cell
analyz
cytokin
product
posit
cytokin
respons
determin
base
percentag
cytokin
respons
obtain
background
respons
unstimul
medium
control
experi
tissu
brain
lung
liver
bilater
kidney
heart
spleen
skull
vertebra
collect
mice
euthan
dead
fix
immers
neutral
buffer
formalin
skull
vertebra
decalcifi
formic
acid
day
sampl
tissu
routin
process
paraffin
section
cut
hematoxylin
eosin
stain
h
e
h
e
section
nasal
olfactori
epithelium
bulb
skull
four
section
spinal
cord
includ
two
consecut
anterior
cervicothorac
two
consecut
lumbarsacr
posterior
section
vertebra
examin
light
microscop
graphic
present
statist
analysi
result
perform
twotail
student
pair
ttest
use
graphpad
prism
graphpad
softwar
inc
sandiego
ca
express
immun
mock
challeng
mice
determin
nonparametr
mannwhitney
ttest
statist
analysi
result
consid
signific
p
mous
surviv
analysi
done
graphpad
prism
graphpad
softwar
inc
sandiego
ca
use
gehanbreslowwilcoxin
test
strain
isol
dead
blue
jay
cyanocitta
cristata
louisiana
recent
entir
genom
strain
sequenc
phylogenet
compar
full
wnv
genom
deposit
genebank
e
gene
amplifi
viral
rna
use
specif
primer
describ
section
clone
plasmid
sigma
place
entir
open
read
frame
wnv
e
infram
code
sequenc
result
addit
amino
acid
sequenc
immedi
last
carboxyl
termin
amino
acid
e
glycoprotein
plasmid
transfect
babi
hamster
kidney
cell
e
glycoprotein
express
detect
h
posttransfect
use
antiflag
monoclon
antibodi
antiflag
antibodi
detect
e
glycoprotein
express
transfect
bhk
cell
mocktransfect
bhk
cell
fail
react
antiflag
antibodi
construct
recombin
vsv
express
e
glycoprotein
e
gene
amplifi
primer
engin
uniqu
xhoi
nhei
restrict
site
e
termini
respect
amplifi
e
gene
code
sequenc
clone
within
uniqu
xhoi
nhei
restrict
site
plasmid
contain
indiana
chandipura
g
glycoprotein
gene
respect
fig
recombin
vsv
recov
cotransfect
three
plasmid
encod
vsv
polymeras
subunit
p
l
nucleocapsid
n
purifi
filtrat
extens
plaquepurifi
appropri
insert
wnv
gene
within
vsv
genom
confirm
direct
dna
sequenc
viral
rna
rtpcr
amplif
specif
cdna
region
wnv
e
express
readili
detect
indirect
immunofluoresc
assay
ifa
use
antiflag
monoclon
antibodi
recombin
vsvinfect
bhk
cell
wnv
e
detect
mockinfect
bhk
cell
fig
cell
lysat
cell
infect
recombin
vsv
express
wnv
e
glycoprotein
test
e
glycoprotein
express
western
immunoblot
antiflag
antibodi
readili
detect
major
protein
speci
appar
molecular
mass
approxim
kda
respect
agreement
previou
report
fig
four
group
balbc
mice
harlan
usa
use
vaccinechalleng
experi
four
group
mice
vaccin
intranas
administr
pfu
recombin
viru
day
boost
pfu
day
postvaccin
fig
mice
group
ii
process
immunolog
analys
see
section
group
iii
iv
challeng
pfu
administ
intraperiton
mice
challeng
group
observ
day
clinic
sign
includ
ruffl
fur
ataxia
hunch
postur
lethargi
mortal
vsve
vaccin
boost
anim
exhibit
surviv
mockvaccin
anim
surviv
challeng
p
fig
vaccin
anim
appear
mild
clinic
sign
postchalleng
includ
mild
fur
ruffl
recov
quickli
full
healthi
statu
contrast
mockvaccin
anim
exhibit
sever
clinic
sign
postchalleng
includ
high
degre
fur
ruffl
ataxia
lethargi
eventu
death
postmortem
histopatholog
examin
reveal
none
vaccin
mice
show
central
nervou
system
cn
patholog
compar
mockvaccin
anim
exhibit
sever
neuron
necrosi
lymphoplasmacyt
perivascular
cuf
fig
singl
mous
vaccin
group
die
day
postchalleng
suppur
rhiniti
may
suggest
bacteri
infect
mild
suppur
inflamm
also
observ
viscer
pleura
subpleura
three
mockvaccin
mice
die
day
postchalleng
shown
signific
histopatholog
abnorm
within
tissu
examin
separ
set
experi
mice
vaccin
via
intramuscular
rout
challeng
differ
strain
wnv
week
postboost
vaccin
efficaci
protect
vaccin
mice
shown
abil
mous
sera
neutral
strain
test
standard
plaqu
reduct
neutral
test
prnt
vaccin
anim
develop
strong
neutral
antibodi
respons
day
primari
vaccin
specif
mice
develop
prnt
express
cell
intim
involv
polyclon
activ
immatur
b
cell
therefor
compar
express
vaccin
mockvaccin
mice
vitro
stimul
pmaionomycin
follow
fac
analysi
see
section
experi
reveal
presenc
significantli
higher
popul
cell
vaccin
mice
compar
mockvaccin
mice
mean
valu
versu
vaccin
mockvaccin
mice
respect
p
fig
c
also
indic
observ
differ
mean
fluoresc
intens
fig
antigenspecif
cytokin
respons
determin
vaccin
mockvaccin
mice
specif
wnve
specif
cell
respons
measur
use
cytokin
flow
cytometri
cfc
determin
respons
overal
vaccin
mice
detect
respons
rang
splenic
cell
cell
posit
respons
absent
vaccin
mice
peptid
pool
e
amino
acid
e
amino
acid
appear
contain
cell
epitop
howev
peptid
pool
contain
domin
cell
epitop
one
mice
develop
antigenspecif
respons
wnve
peptid
pool
none
mockvaccin
mice
detect
respons
background
level
lymphocyt
home
marker
gener
associ
extravas
activ
cell
peripher
site
inflamm
gener
increas
percentag
cell
present
vaccin
mice
compar
mockvaccin
mice
mean
vaccin
mockvaccin
mice
respect
p
fig
cell
subset
vaccin
mice
lower
express
compar
mockvaccin
mice
p
fig
character
cell
respons
induc
cytokin
respons
antigenspecif
cytokin
posit
cell
determin
signific
popul
posit
cell
memori
cell
fig
earli
activ
marker
indic
presenc
antigenspecif
stimul
matur
cell
upregul
activ
cell
detect
vaccin
mice
follow
antigen
stimul
compar
mockvaccin
mice
mean
versu
vaccin
mockvaccin
mice
p
indic
especif
stimul
matur
cell
vaccin
anim
fig
initi
determin
cell
percentag
splenocyt
reveal
signific
differ
vaccin
mockvaccin
mice
fig
receptor
combin
receptor
use
defin
rel
abund
reg
cell
within
popul
convent
cell
analysi
low
cell
reveal
vaccin
mice
significantli
lower
popul
cell
mean
comparison
mockvaccin
mice
mean
p
fig
c
vsvvector
vaccin
shown
except
promis
protect
anim
human
differ
viral
bacteri
pathogen
vsvvector
vaccin
express
wnve
glycoprotein
construct
found
effici
protect
mice
intranas
administr
lethal
wnv
challeng
salient
featur
vaccin
studi
primeboost
intranas
vaccin
approach
recombin
vsv
express
wnv
e
glycoprotein
produc
robust
cell
respons
vaccin
approach
produc
strong
neutral
titer
wnv
vaccin
mice
protect
lethal
challeng
free
neuron
necrosi
unvaccin
mice
statist
signific
differ
observ
two
group
b
repres
dot
plot
show
gate
strategi
reg
cell
deriv
spleenocyt
cell
first
gate
plot
low
cell
defin
reg
c
percentag
low
reg
cell
statist
signific
differ
p
observ
wnvvaccin
mockvaccin
mice
exhibit
sever
neuron
necrosi
inflamm
brain
result
suggest
primeboost
vsvvector
intranas
vaccin
approach
induc
strong
humor
cellular
immun
respons
protect
mice
wnvinduc
neuron
necrosi
mucos
surfac
constitut
natur
rout
vsv
infect
vsv
primarili
veterinari
viral
pathogen
infect
cattl
hors
sheep
anim
vsv
infect
anim
via
transmucos
transcutan
rout
vsv
may
also
transmit
sandfli
blackfli
mosquito
vsv
g
glycoprotein
potent
immunogen
also
serv
import
function
virusentri
virusinduc
cell
fusion
recombin
vsv
express
varieti
viral
bacteri
antigen
construct
vaccin
studi
recombin
vsv
show
intranas
intramuscular
administr
rvsv
safe
effici
induc
protect
humor
cellular
immun
respons
varieti
pathogen
particular
interest
abil
vsvvector
system
elicit
strong
humor
cellular
immun
respons
via
intranas
rout
substanti
easier
administ
intramuscularli
inject
vaccin
vaccin
studi
although
empti
vsv
vector
elicit
robust
humor
cellular
immun
respons
vsv
respons
contribut
protect
varieti
pathogen
indic
specif
immun
respons
express
transgen
primarili
respons
protect
construct
rvsv
express
wnve
glycoprotein
either
vsv
indiana
g
glycoprotein
chandipura
vesiculoviru
g
glycoprotein
pair
rvsv
use
primeboostvaccin
approach
maxim
humor
immun
respons
wnve
glycoprotein
express
virus
minim
anamnest
immun
respons
vsv
vector
target
predominantli
g
glycoprotein
larg
accomplish
chandipura
g
vsvindiana
g
glycoprotein
approxim
differ
amino
acid
sequenc
recombin
vsv
known
nonspecif
incorpor
certain
viral
cellular
glycoprotein
virion
without
advers
affect
viral
infect
insert
foreign
e
gene
vsv
genom
advers
affect
viral
replic
infect
rvsv
contain
e
gene
replic
similar
titer
vsv
control
viru
foreign
gene
insert
within
genom
shown
moreov
rvsve
isol
stabl
sinc
multipl
serial
passag
viru
stock
bhk
cell
affect
e
glycoprotein
express
genom
stabil
shown
although
unclear
whether
wnv
e
glycoprotein
insert
vsv
envelop
result
suggest
rvsve
stabl
retain
wildtyp
level
viral
replic
infect
recombin
vsve
express
wnve
glycoprotein
high
level
bhk
cell
express
e
glycoprotein
appear
fulli
glycosyl
evidenc
appar
molecular
mass
approxim
kda
sdspage
agreement
publish
report
base
known
strong
immun
respons
gener
vsv
especi
administ
via
intranas
rout
devis
experiment
vaccin
protocol
vaccin
mice
intranas
rout
use
primeboost
strategi
primeboostvaccin
approach
result
mice
surviv
lethal
challeng
virul
strain
singl
mous
vaccin
group
mice
die
late
experi
day
postchalleng
appear
die
wnvunrel
caus
sinc
histopatholog
examin
show
sever
suppur
rhiniti
histolog
abnorm
brain
therefor
rvsve
primeboost
intranas
vaccin
protocol
highli
efficaci
protect
mice
wnv
infect
similar
result
obtain
differ
experi
mice
vaccin
via
intramuscular
rout
challeng
strain
instead
week
postboost
experi
mice
surviv
indic
intramuscular
immun
may
also
provid
protect
immun
respons
wnv
infect
primari
wnv
infect
thought
result
local
replic
viru
peripher
organ
viremia
ultim
result
viru
invad
cn
wnv
mortal
thought
larg
caus
replic
viru
cn
tissu
anim
result
immunopatholog
damag
cn
tissu
accordingli
unvaccin
mice
show
obviou
clinic
sign
neurolog
diseas
ataxia
hunch
postur
lethargi
hindlimb
paralysi
histopatholog
examin
brain
tissu
show
neuron
necrosi
perivascular
cuf
microgliosi
contrast
vaccin
mice
develop
mild
clinic
sign
mild
ruffl
fur
recov
quickli
importantli
none
vaccin
mice
exhibit
neuron
necrosi
interact
b
cell
cell
result
cell
mediat
activ
b
cell
result
immunoglobulin
class
switch
somat
hypermut
prolifer
accordingli
cell
upregul
vaccin
control
mice
indic
gener
cell
mediat
b
cell
activ
specif
respons
discern
sinc
may
due
either
vsv
wnv
antigen
howev
strong
neutral
antibodi
titer
also
produc
wnv
indic
induct
especif
humor
immun
respons
result
agreement
previou
report
show
vsvvector
vaccin
induc
strong
humor
immun
respons
differ
vsvexpress
antigen
specif
recombin
vsv
express
either
respiratori
syncyti
viru
f
glycoprotein
rvsv
express
sever
acut
respiratori
syndrom
sar
corona
viru
sarscov
produc
high
antibodi
titer
f
glycoprotein
sarccov
spike
glycoprotein
strong
immun
respons
vsv
viru
note
wnv
e
glycoprotein
contain
multipl
predict
experiment
verifi
cytotox
cell
ctl
epitop
avail
librari
overlap
peptid
deriv
wnv
e
glycoprotein
allow
elucid
antigenspecif
cellular
immun
respons
peptid
pool
compos
first
peptid
averag
amino
acid
gener
stronger
cellular
cell
respons
vitro
prolifer
assay
comparison
peptid
pool
repres
carboxyl
terminushalf
wnv
e
glycoprotein
peptid
pool
contain
experiment
verifi
ctl
epitop
rsycylat
e
peptid
pool
contain
ctl
epitop
ialtflav
shown
confer
protect
lethal
wnvchalleng
mice
vitro
stimul
lymphocyt
vaccin
mice
reveal
presenc
antigenspecif
respons
specif
low
cell
lselectin
mediat
adhes
rest
lymphocyt
peripher
lymph
node
typic
high
express
hi
reveal
entrap
lymphocyt
within
lymph
node
low
low
cellsurfac
express
result
cell
activ
indic
lymphocyt
extravas
site
inflamm
splenocyt
vaccin
mice
significantli
lower
express
marker
especif
cell
reveal
activ
extravas
cell
peripher
site
potenti
involv
kill
virusinfect
cell
prior
transmiss
cn
earli
activ
marker
absent
rest
lymphocyt
upregul
especif
cell
respons
vaccin
versu
mockvaccin
mice
provid
addit
evid
stimul
cell
accordingli
especif
popul
cell
upregul
vaccin
versu
mockvaccin
mice
indic
gener
activ
memori
cell
unclear
whether
observ
cell
memori
respons
confer
longterm
immun
wnv
infect
reg
known
play
import
role
downregul
antiself
immun
respons
suppress
prolifer
cytokin
product
effector
cell
typic
viral
infect
upregul
humor
cellular
immun
respons
caus
downregul
reg
activ
typic
reg
express
marker
receptor
marker
express
invers
correl
express
low
cell
shown
posit
consequ
low
popul
use
defin
reg
expect
neg
correl
rel
popul
reg
cell
low
antigenspecif
ctl
respons
vaccin
mice
howev
specif
immun
respons
discern
sinc
like
caus
vsv
e
glycoprotein
antigen
varieti
experiment
vaccin
approach
report
gener
protect
humor
cellular
immun
respons
flavivirus
specif
wnv
rel
role
humor
versu
cellular
immun
respons
extens
debat
literatur
certain
studi
suggest
strong
humor
immun
respons
evidenc
product
high
titer
antiwnv
titer
necessari
suffici
protect
mice
cn
infect
report
argu
cellular
immun
respons
character
robust
antiwnv
cell
respons
necessari
protect
clear
brain
tissu
wnv
one
report
argu
ctlimmun
respons
may
result
exacerb
immunopatholog
brain
cn
tissu
infect
low
wnv
titer
pfu
experi
wnv
pfu
inocul
intraperiton
vaccin
mice
evid
neuron
necrosi
suggest
cell
respons
confer
protect
viru
clearanc
probabl
humor
cellular
immun
respons
gener
wnv
e
glycoprotein
prevent
viru
enter
cn
potenti
arrest
viru
peripher
site
altern
viru
escap
peripher
immun
surveil
possibl
ctl
clear
viru
brain
tissu
could
caus
signific
damag
result
immunopatholog
manifest
summari
vsvevector
vaccin
appear
elicit
robust
humor
cellular
immun
respons
effici
protect
mice
wnv
lethal
challeng
intranas
vaccin
second
oral
vaccin
regard
rel
eas
administr
patient
complianc
issu
render
approach
attract
human
use
recent
singlecycl
vsvvector
vaccin
shown
gener
robust
immun
respons
number
viral
pathogen
includ
hiv
ebola
marburg
lassa
influenza
avian
influenza
hepat
c
rsv
virus
base
result
expect
singl
cycl
vsvwnv
vaccin
would
also
efficaci
addit
improv
attenu
vsv
made
provid
one
viral
protein
tran
complement
cell
well
engin
addit
mutat
known
attenu
vsv
